Infectious Disease Molecular Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents), By Technology (PCR, ISH, INAAT), By End-use, By Application, By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The global infectious disease molecular diagnostics market size was exhibited at USD 34.94 billion in 2022 and is projected to hit around USD 47.41 billion by 2032, growing at a CAGR of 3.1% during the forecast period 2023 to 2032.

Infectious Disease Molecular Diagnostics Market Size, 2023 to 2032

Key Pointers:

  • North America dominated the market for infectious disease molecular diagnostics and accounted for the largest revenue share of 37.9% in 2022.
  • In Asia Pacific, the market for infectious disease molecular diagnostics is expected to grow fast over the forecast period 
  • The reagents segment dominated the market for infectious disease molecular diagnostics and accounted for the largest revenue share of 69.7% in 2020.
  • The instrument segment is projected to grow at a lucrative rate over the forecast period. 
  • The PCR segment dominated the market for infectious disease molecular diagnostics and accounted for the largest revenue share of 93.4% in 2022.
  • The Human Papillomavirus (HPV) segment is projected to witness a lucrative CAGR of 9.11% over the forecast period.
  • The diagnostic laboratories segment dominated the market for infectious disease molecular diagnostics and accounted for the largest revenue share of 78.19% in 2022 
  • The clinics' segment is expected to witness the fastest growth rate over the forecast period. 

Infectious Disease Molecular Diagnostics Market Report Scope

Report Coverage Report Coverage
Market Size in 2023 USD 36.02 Billion
Market Size by 2032 USD 47.41 Billion
Growth Rate From 2023 to 2032 3.1%
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered Product, End-use, Technology, Application
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)
Regional Scope North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa
Key Companies Profiled Abbott; Becton, Dickinson and Company; bioMérieux SA; Bio-Rad Laboratories, Inc.; Agilent Technologies, Inc.; Danaher Corporation; Hologic, Inc. (Gen-Probe); Illumina, Inc.; Grifols S.A.; Qiagen; F. Hoffmann-La Roche Ltd, Siemens Healthineers AG; Sysmex Corporation

Infectious diseases refer to the diseases caused by various organisms such as bacteria, virus, parasites, and fungi and can be passed from individual to individual or even from animal to individuals such as rabies. Early and accurate detection of infectious diseases is of utmost importance as it spread from one person to another. Molecular diagnostics serve as an effective tool for the detection of HIV, HPV, and other infectious diseases.

There is active support from the government to tackle the rising prevalence and economic burden of infectious diseases. Also, strategic collaboration and the launch of new molecular diagnostic platforms or instruments have surged the market. Awareness and shift towards personalized medicines and preventive care are expected to further enhance the demand for infectious disease diagnostic techniques.

The global infectious disease molecular diagnostics market is anticipated to grow owing to the increasing prevalence of infectious diseases, rising awareness regarding prevention and early diagnosis of sexually transmitted diseases, and active government support. The World Health Organization (WHO) estimated that there were approximately 36.9 million individuals diagnosed with HIV at the end of 2017, with a new 1.8 million people diagnosed in 2017 globally. These trends, combined with the other factors, are expected to drive the growth in the infectious disease molecular diagnostics market growth during the forecast duration.

However, lack of skilled labor in developing countries, high installation and infrastructure cost can hinder the growth in the global infectious disease molecular diagnostics market. 

North America is estimated to dominate the global infectious disease molecular diagnostics market over the forecast period due to the increasing prevalence of infectious diseases such as HIV and respiratory diseases, established healthcare system, and increased R&D investment. Asia Pacific is projected to report significant growth in the global infectious disease molecular diagnostics market due to active government support, improving access to the advanced diagnostic facility and rapid adoption of preventive care.

Some of the prominent players in the Infectious Disease Molecular Diagnostics Market include:

  • Abbott
  • Danaher Corporation
  • bioMérieux SA
  • F. Hoffmann-La Roche Ltd
  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Hologic, Inc. (Gen-Probe)
  • Illumina, Inc.
  • Grifols S.A.
  • Qiagen
  • Siemens Healthineers AG
  • Sysmex Corporation

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Infectious Disease Molecular Diagnostics market.

By Product 

  • Instruments
  • Reagents
  • Services

By End-use 

  • Hospitals
  • Clinics
  • Diagnostics Laboratories
  • Research Institutes

By Technology 

  • Polymerase chain reaction (PCR)
    • PCR, by Type
      • Multiplex PCR
      • Other PCR
    • PCR, by Product
      • Instruments
      • Reagents
      • Services
  • In Situ Hybridization
    • Instruments
    • Reagents
    • Services
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • Instruments
    • Reagents
    • Services
  • Chips and Microarrays
    • Instruments
    • Reagents
    • Services
  • Mass Spectrometry
    • Instruments
    • Reagents
    • Services
  • Sequencing
    • Instruments
    • Reagents
    • Services
  • Transcription Mediated Amplification
    • Instruments
    • Reagents
    • Services
  • Others
    • Instruments
    • Reagents
    • Services

By Application 

  • Respiratory Diseases
  • Tuberculosis
  • Meningitis
  • Gastrointestinal Tract Infections
  • HPV
  • Sexually Transmitted Infections
  • Sepsis
  • Drug Resistance Diseases
  • Other Infectious Diseases

By Respiratory Diseases 

  • Respiratory Diseases, By Product 
    • Instruments
    • Reagents
    • Services
  • By Respiratory Diseases, By End Use 
    • Hospitals
    • Clinics
    • Diagnostics Laboratories
    • Research Institutes
  • Respiratory Diseases, By Technology
    • Polymerase chain reaction (PCR)
    • In Situ Hybridization
    • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • Chips and Microarrays
    • Mass Spectrometry
    • Sequencing
    • Transcription Mediated Amplification
    • Others

By Tuberculosis 

  • Tuberculosis, By Product 
    • Instruments
    • Reagents
    • Services
  • Tuberculosis, By End Use 
    • Hospitals
    • Clinics
    • Diagnostics Laboratories
    • Research Institutes
  • Tuberculosis, By Technology
    • Polymerase chain reaction (PCR)
    • In Situ Hybridization
    • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • Chips and Microarrays
    • Mass Spectrometry
    • Sequencing
    • Transcription Mediated Amplification
    • Others

By Meningitis 

  • Meningitis, By Product 
    • Instruments
    • Reagents
    • Services
  • Meningitis, By End Use 
    • Hospitals
    • Clinics
    • Diagnostics Laboratories
    • Research Institutes
  • Meningitis, By Technology
    • Polymerase chain reaction (PCR)
    • In Situ Hybridization
    • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • Chips and Microarrays
    • Mass Spectrometry
    • Sequencing
    • Transcription Mediated Amplification
    • Others

By Gastrointestinal Tract Infections 

  • Gastrointestinal Tract Infections, By Product
    • Instruments
    • Reagents
    • Services
  • Gastrointestinal Tract Infections, By End Use 
    • Hospitals
    • Clinics
    • Diagnostics Laboratories
    • Research Institutes
  • By Gastrointestinal Tract Infections, By Technology
    • Polymerase chain reaction (PCR)
    • In Situ Hybridization
    • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • Chips and Microarrays
    • Mass Spectrometry
    • Sequencing
    • Transcription Mediated Amplification
    • Others

By HPV 

  • HPV, By Product 
    • Instruments
    • Reagents
    • Services
  • HPV, By End Use 
    • Hospitals
    • Clinics
    • Diagnostics Laboratories
    • Research Institutes
  • HPV, By Technology
    • Polymerase chain reaction (PCR)
    • In Situ Hybridization
    • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • Chips and Microarrays
    • Mass Spectrometry
    • Sequencing
    • Transcription Mediated Amplification
    • Others

By Sexually Transmitted Infections 

  • Sexually Transmitted Infections, By Product 
    • Instruments
    • Reagents
    • Services
  • Sexually Transmitted Infections, By End Use 
    • Hospitals
    • Clinics
    • Diagnostics Laboratories
    • Research Institutes
  • Sexually Transmitted Infections, By Technology
    • Polymerase chain reaction (PCR)
    • In Situ Hybridization
    • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • Chips and Microarrays
    • Mass Spectrometry
    • Sequencing
    • Transcription Mediated Amplification
    • Others

By Sepsis 

  • Sepsis, By Product 
    • Instruments
    • Reagents
    • Services
  • Sepsis, By End Use 
    • Hospitals
    • Clinics
    • Diagnostics Laboratories
    • Research Institutes
  • Sepsis, By Technology
    • Polymerase chain reaction (PCR)
    • In Situ Hybridization
    • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • Chips and Microarrays
    • Mass Spectrometry
    • Sequencing
    • Transcription Mediated Amplification
    • Others

By Drug Resistance Disease 

  • By Drug Resistance Disease, By Product 
    • Instruments
    • Reagents
    • Services
  • By Drug Resistance Disease, By End Use 
    • Hospitals
    • Clinics
    • Diagnostics Laboratories
    • Research Institutes
  • By Drug Resistance Disease, By Technology
    • Polymerase chain reaction (PCR)
    • In Situ Hybridization
    • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • Chips and Microarrays
    • Mass Spectrometry
    • Sequencing
    • Transcription Mediated Amplification
    • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

The global infectious disease molecular diagnostics market size was exhibited at USD 34.94 billion in 2022 and is projected to hit around USD 47.41 billion by 2032

The global infectious disease molecular diagnostics market is expected to grow at a compound annual growth rate of 3.1% from 2023 to 2032

Some key players operating in the infectious disease molecular diagnostics market include Abbott, Danaher Corporation, bioMérieux SA, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Becton, Dickinson and Company, Hologic, Inc. (Gen-Probe), Illumina, Inc., Grifols S.A., Qiagen, Siemens Healthineers AG, and Sysmex Corporation.

Key factors that are driving the market growth include the growing use of molecular diagnostics in infection detection, the rising geriatric population, and the increasing demand for point-of-care molecular diagnostics for the management of a growing number of infections.

Chapter 1 Methodology and Scope
                   1.1 Market Segmentation and Scope
                       1.1.1 Regional scope
                       1.1.2 Estimates and forecast timeline
                   1.2 Research Methodology
                   1.3 Information procurement
                       1.3.1 Purchased database:
                       1.3.2 Nova One Advisor internal database
                       1.3.3 Secondary sources
                       1.3.4 Primary research
                   1.4 Information or Data Analysis
                       1.4.1 Data analysis models
                   1.5 Market Formulation & Validation
                   1.6 Model Details
                       1.6.1 Commodity Flow Analysis (Model 1)
                           1.6.1.1 Approach 1: Commodity Flow Approach
                   1.7 Research Assumptions
                   1.8 List of Secondary Sources
                   1.9 List of Abbreviations
                   1.10 Objectives
                       1.10.1 Objective 1
                       1.10.2 Objective 2
                       1.10.3 Objective 3
                       1.10.4 Objective 4
Chapter 2 Executive Summary
                   2.1 Market Outlook
Chapter 3 Infectious Disease Molecular Diagnostics Market Variables, Trends & Scope
                   3.1 Infectious Disease Molecular Diagnostics Market Lineage Outlook
                       3.1.1 Parent market outlook
                   3.2 User Perspective Analysis
                   3.3 Penetration & Growth Prospect Mapping
                   3.4 Regulatory and Reimbursement Framework
                   3.5 Market Dynamics
                       3.5.1 Market driver analysis
                           3.5.1.1 Increase in geriatric population
                           3.5.1.2 Introduction of technologically advanced products
                           3.5.1.3 Increase in demand for point-of-care Daignostics
                           3.5.1.4 Growing prevalence of target diseases
                           3.5.1.5 Increasing external funding for R&D
                           3.5.1.6 Outbreak of COVID-19
                       3.5.2 Market restraint analysis
                           3.5.2.1 Presence of ambiguous regulatory framework
                           3.5.2.2 High prices of Infectious Disease Molecular Diagnostics tests
                   3.6 Infectious Disease Molecular Diagnostics Market Analysis Tools
                       3.6.1 Porter’s Five Forces Analysis
                       3.6.2 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
                       3.6.3 Major deals & strategic alliances analysis
                           3.6.3.1 New product launch
                           3.6.3.2 Mergers and acquisitions
                           3.6.3.3 Expansion
                           3.6.3.4 Partnerships
                           3.6.3.5 Market entry strategies
Chapter 4 Products Business Analysis
                   4.1 Infectious Disease Molecular Diagnostics Market: Products Movement Analysis
                       4.1.1 Instruments
                           4.1.1.1 Instruments market estimates and forecast, 2020 - 2032
                       4.1.2 Reagents
                           4.1.2.1 Reagents market estimates and forecast, 2020 - 2032
                       4.1.3 Services
                           4.1.3.1 Services market estimates and forecast, 2020 - 2032
Chapter 5 Technology Business Analysis
                   5.1 Infectious Disease Molecular Diagnostics Market: Technology Movement Analysis
                       5.1.1 Polymerase Chain Reaction
                           5.1.1.1 Polymerase chain reaction market estimates and forecast, 2020 - 2032
                           5.1.1.2 PCR Market by type
                               5.1.1.2.1 Multiplex PCR
                                   5.1.1.2.1.1 Multiplex PCR market estimates and forecast, 2020 - 2032
                               5.1.1.2.2 Other PCR
                                   5.1.1.2.2.1 Other PCR market estimates and forecast, 2020 - 2032
                           5.1.1.3 PCR market, by Product
                               5.1.1.3.1 Instruments
                                   5.1.1.3.1.1 Instruments PCR market estimates and forecast, 2020 - 2032
                               5.1.1.3.2 Reagents
                                   5.1.1.3.2.1 Reagents PCR market estimates and forecast, 2020 - 2032
                               5.1.1.3.3 Services
                                   5.1.1.3.3.1 Services PCR market estimates and forecast, 2020 - 2032
                       5.1.2 In Situ Hybridization (ISH)
                           5.1.2.1 In Situ Hybridization market estimates and forecast, 2020 - 2032
                           5.1.2.2 Instruments
                               5.1.2.2.1 Instruments ISH market estimates and forecast, 2020 - 2032
                           5.1.2.3 Reagents
                               5.1.2.3.1 Reagents ISH market estimates and forecast, 2020 - 2032
                           5.1.2.4 Others
                               5.1.2.4.1 Others ISH market estimates and forecast, 2020 - 2032
                       5.1.3 Isothermal Nucleic Acid Amplification Technology (INAAT)
                           5.1.3.1 INAAT market estimates and forecast, 2020 - 2032
                           5.1.3.2 Instruments
                               5.1.3.2.1 Instruments INAAT market estimates and forecast, 2020 - 2032
                           5.1.3.3 Reagents
                               5.1.3.3.1 Reagents INAAT market estimates and forecast, 2020 - 2032
                           5.1.3.4 Services
                               5.1.3.4.1 Services INAAT market estimates and forecast, 2020 - 2032
                       5.1.4 Chips and Microarrays
                           5.1.4.1 Chips and Microarrays market estimates and forecast, 2020 - 2032
                           5.1.4.2 Instruments
                               5.1.4.2.1 Instruments chips and microarrays market estimates and forecast, 2020 - 2032
                           5.1.4.3 Reagents
                               5.1.4.3.1 Reagents chips and microarrays market estimates and forecast, 2020 - 2032
                           5.1.4.4 Services
                               5.1.4.4.1 Services chips and microarrays market estimates and forecast, 2020 - 2032
                       5.1.5 Mass Spectrometry
                           5.1.5.1 Mass Spectrometry market estimates and forecast, 2020 - 2032
                           5.1.5.2 Instruments
                               5.1.5.2.1 Instruments mass spectrometry market estimates and forecast, 2020 - 2032
                           5.1.5.3 Reagents
                               5.1.5.3.1 Reagents mass spectrometry market estimates and forecast, 2020 - 2032
                           5.1.5.4 Services
                               5.1.5.4.1 Services mass spectrometry market estimates and forecast, 2020 - 2032
                       5.1.6 Sequencing
                           5.1.6.1 Sequencing market estimates and forecast, 2020 - 2032
                           5.1.6.2 Instruments
                               5.1.6.2.1 Instruments sequencing market estimates and forecast, 2020 - 2032
                           5.1.6.3 Reagents
                               5.1.6.3.1 Reagents sequencing market estimates and forecast, 2020 - 2032
                           5.1.6.4 Services
                               5.1.6.4.1 Services sequencing market estimates and forecast, 2020 - 2032
                       5.1.7 Transcription Mediated Amplification (TMA)
                           5.1.7.1 TMA market estimates and forecast, 2020 - 2032
                           5.1.7.2 Instruments
                               5.1.7.2.1 Instruments TMA market estimates and forecast, 2020 - 2032
                           5.1.7.3 Reagents
                               5.1.7.3.1 Reagents TMA market estimates and forecast, 2020 - 2032
                           5.1.7.4 Services
                               5.1.7.4.1 Services TMA market estimates and forecast, 2020 - 2032
                       5.1.8 Others
                           5.1.8.1 Others market estimates and forecast, 2020 - 2032
                           5.1.8.2 Instruments
                               5.1.8.2.1 Instruments others market estimates and forecast, 2020 - 2032
                           5.1.8.3 Reagents
                               5.1.8.3.1 Reagents others market estimates and forecast, 2020 - 2032
                           5.1.8.4 Services
                               5.1.8.4.1 Services market estimates and forecast, 2020 - 2032
Chapter 6 End-use Business Analysis
                   6.1 Molecular Diagnostics Market: End-use Movement Analysis
                       6.1.1 Hospitals
                           6.1.1.1 Hospitals market estimates and forecast, 2020 - 2032
                       6.1.2 Clinics
                           6.1.2.1 Clinics market estimates and forecast, 2020 - 2032
                       6.1.3 Diagnostic laboratories
                           6.1.3.1 Diagnostic laboratories market estimates and forecast, 2020 - 2032
                       6.1.4 Research Institutes
                           6.1.4.1 Research Institutes market estimates and forecast, 2020 - 2032
Chapter 7 Application Business Analysis
                   7.1 Molecular Diagnostics Market: Application Movement Analysis
                       7.1.1 Respiratory Diseases
                           7.1.1.1 Respiratory diseases market estimates and forecast, 2020 - 2032
                       7.1.2 Tuberculosis
                           7.1.2.1 Tuberculosis market estimates and forecast, 2020 - 2032
                       7.1.3 Meningitis
                           7.1.3.1 Meningitis market estimates and forecast, 2020 - 2032
                       7.1.4 Gastrointestinal Tract Infections
                           7.1.4.1 Gastrointestinal tract infections market estimates and forecast, 2020 - 2032
                       7.1.5 HPV
                           7.1.5.1 HPV market estimates and forecast, 2020 - 2032
                       7.1.6 Sexually Transmitted Infections
                           7.1.6.1 Sexually transmitted infections market estimates and forecast, 2020 - 2032
                       7.1.7 Sepsis
                           7.1.7.1 Sepsis market estimates and forecast, 2020 - 2032
                       7.1.8 Drug Resistance Disease
                           7.1.8.1 Drug resistance disease market estimates and forecast, 2020 - 2032
                       7.1.9 Other Infectious Diseases
                           7.1.9.1 Other infectious diseases market estimates and forecast, 2020 - 2032
Chapter 8 Respiratory Diseases Molecular Diagnostics Market Analysis, 2020 - 2032,
                   8.1 Product Movement Analysis & Market Share, 2020 & 2032
                       8.1.1 Instruments
                       8.1.2 Reagents
                       8.1.3 Services
                   8.2 End-use Movement Analysis & Market Share, 2020 & 2032
                       8.2.1 Hospitals
                       8.2.2 Clinics
                       8.2.3 Diagnostic Laboratories
                       8.2.4 Research Institutes
                   8.3 Technology Movement Analysis & Market Share, 2020 & 2032 (Number of Tests Performed)
                       8.3.1 Polymerase Chain Reaction (PCR)
                       8.3.2 In Situ Hybridization
                       8.3.3 Isothermal Nucleic Acid Amplification Technology (INAAT)
                       8.3.4 Chips and Microarrays
                       8.3.5 Mass Spectrometry
                       8.3.6 Sequencing
                       8.3.7 Transcription Mediated Amplification
                       8.3.8 Others
Chapter 9 Tuberculosis-Molecular Diagnostics Market Analysis, 2020 - 2032,
                   9.1 Product Movement Analysis & Market Share, 2020 & 2032
                       9.1.1 Instruments
                       9.1.2 Reagents
                       9.1.3 Services
                   9.2 End-use Movement Analysis & Market Share, 2020 & 2032
                       9.2.1 Hospitals
                       9.2.2 Clinics
                       9.2.3 Diagnostic Laboratories
                       9.2.4 Research Institutes
                   9.3 Technology Movement Analysis & Market Share, 2020 & 2032 (Number of Tests Performed)
                       9.3.1 Polymerase Chain Reaction (PCR)
                       9.3.2 In Situ Hybridization
                       9.3.3 Isothermal Nucleic Acid Amplification Technology (INAAT)
                       9.3.4 Chips and Microarrays
                       9.3.5 Mass Spectrometry
                       9.3.6 Sequencing
                       9.3.7 Transcription Mediated Amplification
                       9.3.8 Others
Chapter 10 Meningitis-Molecular Diagnostics Market Analysis, 2020 - 2032,
                   10.1 Product Movement Analysis & Market Share, 2020 & 2032
                       10.1.1 Instruments
                       10.1.2 Reagents
                       10.1.3 Services
                   10.2 End-use Movement Analysis & Market Share, 2020 & 2032
                       10.2.1 Hospitals
                       10.2.2 Clinics
                       10.2.3 Diagnostic Laboratories
                       10.2.4 Research Institutes
                   10.3 Technology Movement Analysis & Market Share, 2020 & 2032 (Number of Tests Performed)
                       10.3.1 Polymerase Chain Reaction (PCR)
                       10.3.2 In Situ Hybridization
                       10.3.3 Isothermal Nucleic Acid Amplification Technology (INAAT)
                       10.3.4 Chips and Microarrays
                   10.3.5 Mass Spectrometry
                       10.3.6 Sequencing
                       10.3.7 Transcription Mediated Amplification
                       10.3.8 Others
Chapter 11 Gastrointestinal Tract Infections-Molecular Diagnostics Market Analysis, 2020- 2032,
                   11.1 Product Movement Analysis & Market Share, 2020 & 2032
                       11.1.1 Instruments
                       11.1.2 Reagents
                       11.1.3 Services
                   11.2 End-use Movement Analysis & Market Share, 2020 & 2032
                       11.2.1 Hospitals
                       11.2.2 Clinics
                       11.2.3 Diagnostic Laboratories
                       11.2.4 Research Institutes
                   11.3 Technology Movement Analysis & Market Share, 2020 & 2032 (Number of Tests Performed)
                       11.3.1 Polymerase Chain Reaction (PCR)
                       11.3.2 In Situ Hybridization
                       11.3.3 Isothermal Nucleic Acid Amplification Technology (INAAT)
                       11.3.4 Chips and Microarrays
                       11.3.5 Mass Spectrometry
                       11.3.6 Sequencing
                       11.3.7 Transcription Mediated Amplification
                       11.3.8 Others
Chapter 12 HPV-Molecular Diagnostics Market Analysis, 2020 - 2032,
                   12.1 Product Movement Analysis & Market Share, 2020 & 2032
                       12.1.1 Instruments
                       12.1.2 Reagents
                       12.1.3 Services
                   12.2 End-use Movement Analysis & Market Share, 2020 & 2032
                       12.2.1 Hospitals
                       12.2.2 Clinics
                       12.2.3 Diagnostic Laboratories
                       12.2.4 Research Institutes
                   12.3 Technology Movement Analysis & Market Share, 2020 & 2032 (Number of Tests Performed)
                       12.3.1 Polymerase Chain Reaction (PCR)
                       12.3.2 In Situ Hybridization
                       12.3.3 Isothermal Nucleic Acid Amplification Technology (INAAT)
                       12.3.4 Chips and Microarrays
                       12.3.5 Mass Spectrometry
                       12.3.6 Sequencing
                       12.3.7 Transcription Mediated Amplification
                       12.3.8 Others
Chapter 13 Sexually Transmitted Infections-Molecular Diagnostics Market Analysis, 2020- 2032,
                   13.1 Product Movement Analysis & Market Share, 2020 & 2032
                       13.1.1 Instruments
                       13.1.2 Reagents
                       13.1.3 Services
                   13.2 End-use Movement Analysis & Market Share, 2020 & 2032
                       13.2.1 Hospitals
                       13.2.2 Clinics
                       13.2.3 Diagnostic Laboratories
                       13.2.4 Research Institutes
                   13.3 Technology Movement Analysis & Market Share, 2020 & 2032 (Number of Tests Performed)
                       13.3.1 Polymerase Chain Reaction (PCR)
                       13.3.2 In Situ Hybridization
                       13.3.3 Isothermal Nucleic Acid Amplification Technology (INAAT)
                       13.3.4 Chips and Microarrays
                       13.3.5 Mass Spectrometry
                       13.3.6 Sequencing
                       13.3.7 Transcription Mediated Amplification
                       13.3.8 Others
Chapter 14 Sepsis-Molecular Diagnostics Market Analysis, 2020 - 2032,
                   14.1 Product Movement Analysis & Market Share, 2020 & 2032
                       14.1.1 Instruments
                       14.1.2 Reagents
                       14.1.3 Services
                   14.2 End-use Movement Analysis & Market Share, 2020 & 2032
                       14.2.1 Hospitals
                       14.2.2 Clinics
                       14.2.3 Diagnostic Laboratories
                       14.2.4 Research Institutes
                   14.3 Technology Movement Analysis & Market Share, 2020 & 2032 (Number of Tests Performed)
                       14.3.1 Polymerase Chain Reaction (PCR)
                       14.3.2 In Situ Hybridization
                       14.3.3 Isothermal Nucleic Acid Amplification Technology (INAAT)
                       14.3.4 Chips and Microarrays
                       14.3.5 Mass Spectrometry
                       14.3.6 Sequencing
                       14.3.7 Transcription Mediated Amplification
                       14.3.8 Others
Chapter 15 Drug Resistance Infections-Molecular Diagnostics Market Analysis, 2020 - 2032,
                   15.1 Product Movement Analysis & Market Share, 2020 & 2032
                       15.1.1 Instruments
                       15.1.2 Reagents
                       15.1.3 Services
                   15.2 End-use Movement Analysis & Market Share, 2020 & 2032
                       15.2.1 Hospitals
                       15.2.2 Clinics
                       15.2.3 Diagnostic Laboratories
                       15.2.4 Research Institutes
                   15.3 Technology Movement Analysis & Market Share, 2020 & 2032 (Number of Tests Performed)
                       15.3.1 Polymerase Chain Reaction (PCR)
                       15.3.2 In Situ Hybridization
                       15.3.3 Isothermal Nucleic Acid Amplification Technology (INAAT)
                       15.3.4 Chips and Microarrays
                       15.3.5 Mass Spectrometry
                       15.3.6 Sequencing
                       15.3.7 Transcription Mediated Amplification
                       15.3.8 Others
Chapter 16 Infectious Disease Molecular Diagnostics Market: Regional Market Analysis, 2020 - 2032
                   16.1 Definition & Scope
                   16.2 Regional Market Share Analysis, 2020 & 2032
                   16.3 Regional Market Dashboard
                   16.4 Regional Market Snapshot
                   16.5 Market Size, & Forecasts, Trend Analysis, 2020 to 2032
                   16.6 North America
                       16.6.1 North America Market estimates and forecast, 2020 - 2032
                       16.6.2 U.S.
                           16.6.2.1 U.S. Infectious Disease Molecular Diagnostics Market, 2020 - 2032
                       16.6.3 Canada
                           16.6.3.1 Canada Infectious Disease Molecular Diagnostics Market, 2020 - 2032
                   16.7 Europe
                       16.7.1 Europe Infectious Disease Molecular Diagnostics Market, 2020 - 2032
                       16.7.2 U.K.
                           16.7.2.1 U.K. Infectious Disease Molecular Diagnostics Market, 2020 - 2032
                       16.7.3 Germany
                           16.7.3.1 Germany Infectious Disease Molecular Diagnostics Market, 2020 - 2032
                       16.7.4 Spain
                           16.7.4.1 Spain Infectious Disease Molecular Diagnostics Market, 2020 - 2032
                       16.7.5 France
                           16.7.5.1 France Infectious Disease Molecular Diagnostics Market, 2020 - 2032
                       16.7.6 Italy
                           16.7.6.1 Italy Infectious Disease Molecular Diagnostics Market, 2020 - 2032
                   16.8 Asia Pacific
                       16.8.1 Asia Pacific Infectious Disease Molecular Diagnostics Market, 2020 - 2032
                       16.8.2 Japan
                           16.8.2.1 Japan Infectious Disease Molecular Diagnostics Market, 2020 - 2032
                       16.8.3 China
                           16.8.3.1 China Infectious Disease Molecular Diagnostics Market, 2020 - 2032
                       16.8.4 India
                           16.8.4.1 India Infectious Disease Molecular Diagnostics Market, 2020 - 2032
                       16.8.5 South Korea
                           16.8.5.1 South Korea Infectious Disease Molecular Diagnostics Market, 2020 - 2032
                       16.8.6 Australia
                           16.8.6.1 Australia Infectious Disease Molecular Diagnostics Market, 2020 - 2032
                   16.9 Latin America
                       16.9.1 Latin America Infectious Disease Molecular Diagnostics Market, 2020 - 2032
                       16.9.2 Brazil
                           16.9.2.1 Brazil Infectious Disease Molecular Diagnostics Market, 2020 - 2032
                       16.9.3 Mexico
                           16.9.3.1 Mexico Infectious Disease Molecular Diagnostics Market, 2020 - 2032
                       16.9.4 Argentina
                           16.9.4.1 Argentina Infectious Disease Molecular Diagnostics Market, 2020 - 2032
                   16.10 MEA
                       16.10.1 MEA Infectious Disease Molecular Diagnostics Market, 2020 - 2032
                       16.10.2 South Africa
                           16.10.2.1 South Africa Infectious Disease Molecular Diagnostics Market, 2020 - 2032
                       16.10.3 Saudi Arabia
                           16.10.3.1 Saudi Arabia Infectious Disease Molecular Diagnostics Market, 2020 - 2032
                       16.10.4 UAE
                           16.10.4.1 UAE Infectious Disease Molecular Diagnostics Market, 2020 - 2032
Chapter 17 COMPETITIVE LANDSCAPE
                   17.1 Recent Developments and Impact Analysis, by Key Market Participants
                       17.1.1 Ansoff matrix
                   17.2 Company Categorization
                       17.2.1 Innovators
                       17.2.2 Market Leaders
                   17.3 Vendor Landscape
                       17.3.1 List of key distributors and channel partners
                       17.3.2 Key customers
                   17.4 Public Companies
                       17.4.1 Company market position analysis
                       17.4.2 Competitive Dashboard Analysis
                           17.4.2.1 Market Differentiators
                   17.5 Private Companies
                       17.5.1 List of key emerging companies
                   17.6 Company Profiles
                       17.6.1 Abbott
                           17.6.1.1 Company overview
                           17.6.1.2 Alere, Inc.
                           17.6.1.3 Financial performance
                           17.6.1.4 Product benchmarking
                           17.6.1.5 Strategic initiatives
                       17.6.2 Becton, Dickinson and Company
                           17.6.2.1 Company overview
                           17.6.2.2 Financial performance
                           17.6.2.3 Product benchmarking
                           17.6.2.4 Strategic initiatives
                       17.6.3 bioMérieux SA
                           17.6.3.1 Company overview
                           17.6.3.2 Financial performance
                           17.6.3.3 Product benchmarking
                           17.6.3.4 Strategic initiatives
                       17.6.4 Bio-Rad Laboratories, Inc.
                           17.6.4.1 Company overview
                           17.6.4.2 Financial performance
                           17.6.4.3 Product benchmarking
                           17.6.4.4 Strategic initiatives
                       17.6.5 Agilent Technologies, Inc.
                           17.6.5.1 Company overview
                           17.6.5.2 Financial performance
                           17.6.5.3 Product benchmarking
                           17.6.5.4 Strategic initiatives
                       17.6.6 Danaher Corporation
                           17.6.6.1 Company overview
                           17.6.6.2 Cepheid
                           17.6.6.3 Beckman Coulter
                           17.6.6.4 Leica Biosystems
                           17.6.6.5 Financial performance
                           17.6.6.6 Product benchmarking
                           17.6.6.7 Strategic initiatives
                           17.6.6.8 Strategic initiatives of Cepheid
                       17.6.7 Hologic, Inc. (Gen Probe)
                           17.6.7.1 Company overview
                           17.6.7.2 Financial performance
                           17.6.7.3 Product benchmarking
                           17.6.7.4 Strategic initiatives
                       17.6.8 Illumina, Inc.
                           17.6.8.1 Company overview
                           17.6.8.2 Financial performance
                           17.6.8.3 Product benchmarking
                           17.6.8.4 Strategic initiatives
                       17.6.9 GRIFOLs S.A.
                           17.6.9.1 Company overview
                           17.6.9.2 Financial performance
                           17.6.9.3 Product benchmarking
                           17.6.9.4 Strategic initiatives
                       17.6.10 Qiagen
                           17.6.10.1 Company overview
                           17.6.10.2 Financial performance
                           17.6.10.3 Product benchmarking
                           17.6.10.4 Strategic initiatives
                       17.6.11 F. Hoffmann-La Roche Ltd
                           17.6.11.1 Company overview
                           17.6.11.2 Financial performance
                           17.6.11.3 Product benchmarking
                           17.6.11.4 Strategic initiatives
                       17.6.12 Siemens Healthineers
                           17.6.12.1 Company overview
                           17.6.12.2 Financial performance
                           17.6.12.3 Product benchmarking
                           17.6.12.4 Strategic initiatives
                       17.6.13 Sysmex Corporation
                           17.6.13.1 Company overview
                           17.6.13.2 Financial performance
                           17.6.13.3 Product benchmarking
                           17.6.13.4 Strategic initiatives

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers
Ask To Expert